Table 2. Univariate analysis of relation between clinicopathological factors and platinum-sensitivity status in LS-SCLC.
| Characteristics | Sensitive | Refractory | p |
|---|---|---|---|
| Gender | |||
| Male | 213 (76.3%) | 127 (73.4%) | 0.483 |
| Female | 66 (23.7%) | 46 (26.6%) | |
| Age | |||
| < 65 | 187 (67.0%) | 105 (60.7%) | 0.171 |
| ≥ 65 | 92 (33.0%) | 68 (39.3%) | |
| ECOG PS | |||
| 0–1 | 228 (81.7%) | 129 (74.6%) | 0.07 |
| 2–3 | 51 (18.3%) | 44 (25.4%) | |
| Smoking Status | |||
| Yes | 192 (68.8%) | 130 (75.1%) | 0.149 |
| No | 87 (31.2%) | 43 (24.9%) | |
| Smoking packs | |||
| ≥ 30 packs-year | 128 (87.1%) | 150 (85.7%) | 0.723 |
| < 30 packs-year | 19 (12.9%) | 25 (14.2%) | |
| Treatment modality | |||
| Chemoradiotherapy | 238 (85.3%) | 135 (78.0%) | 0.048 |
| Chemotherapy alone | 41 (14.7%) | 38 (22.0%) | |
| Chemoradiotherapy | |||
| Concurrent | 224 (83.3%) | 79 (76.0%) | 0.179 |
| Sequential | 45 (16.7%) | 25 (24.0%) | |
| Therapy regimen | |||
| Etoposide + platinum | 235 (84.2%) | 141 (81.5%) | 0.451 |
| Irinotecan + platinum | 44 (15.8%) | 32 (18.5%) | |
| Chemotherapy cycles | |||
| N ≥ 4 | 250 (89.6%) | 146 (84.4%) | 0.102 |
| N < 4 | 29 (10.4%) | 27 (15.6%) | |
| Response | |||
| CR + PR | 210 (75.3%) | 105 (60.7%) | 0.001 |
| SD + PD | 69 (24.7%) | 68 (39.3%) | |
| WBC | |||
| Normal (< 10/nl) | 189 (72.7%) | 113 (68.1%) | 0.306 |
| Elevated (≥ 10/nl) | 71 (27.3%) | 53 (31.9%) | |
| LDH | |||
| Normal (< 240 U/l) | 193 (71.5%) | 106 (65.0%) | 0.159 |
| Elevated (≥ 240 U/l) | 77 (28.5%) | 57 (35.0%) | |
| Hemoglobin | |||
| Normal (≥ 110 g/l) | 211 (86.8%) | 131 (84.0%) | 0.426 |
| Decreased (< 110 g/l) | 32 (13.2%) | 25 (16.0%) | |
| Na | |||
| Normal (≥ 135 mM) | 208 (75.9%) | 131 (82.4%) | 0.699 |
| Decreased (< 135 mM) | 66 (24.1%) | 28 (17.6%) | |
| GLUT | |||
| Normal (≤ 45 U/l) | 158 (65.0%) | 107 (68.6%) | 0.461 |
| Elevated (> 45 U/l) | 85 (35.0%) | 49 (31.4%) | |
| PLT | |||
| Inside (100–300*109/l) | 208 (78.8%) | 131 (76.6%) | 0.592 |
| Outside (< 100 or > 300*109/l) | 56 (21.2%) | 40 (23.4%) | |
| Tumor Size | 50.78 ± 20.58 | 53.81 ± 21.67 | 0.149 |
| BMI | 23.56 ± 2.84 | 23.13 ± 2.89 | 0.119 |
| CEA | |||
| At diagnosis | 9.80 ± 3.38 | 10.38 ± 3.89 | 0.11 |
| After four cycles | 8.09 ± 2.75 | 8.52 ± 2.51 | 0.184 |
| At progression | 8.38 ± 3.35 | 8.94 ± 3.06 | 0.276 |
| NSE | |||
| At diagnosis | 44.44 ± 23.28 | 52.26 ± 25.58 | 0.004 |
| After four cycles | 17.96 ± 7.54 | 23.16 ± 10.71 | < 0.001 |
| At progression | 50.27 ± 26.99 | 62.45 ± 33.60 | < 0.001 |
| Cyfra21-1 | |||
| At diagnosis | 2.67 ± 2.43 | 3.07 ± 2.37 | 0.109 |
| After four cycles | 1.86 ± 1.34 | 2.09 ± 1.44 | 0.215 |
| At progression | 2.15 ± 1.70 | 2.41 ± 1.56 | 0.186 |
| NLR | |||
| At diagnosis | 3.83 ± 2.31 | 4.66 ± 2.82 | 0.003 |
| After four cycles | 2.45 ± 1.67 | 4.1 ± 2.56 | < 0.001 |
| At progression | 4.12 ± 2.49 | 5.11 ± 3.09 | 0.003 |
| PLR | |||
| At diagnosis | 178.68 ± 95.34 | 186.18 ± 109.55 | 0.462 |
| After four cycles | 170 ± 95.31 | 179.55 ± 105.55 | 0.362 |
| At progression | 176.77 ± 99.6 | 184.83 ± 98.89 | 0.395 |
Abbreviations: LS-SCLC: limited-stage small cell lung cancer; ECOG PS: Eastern Cooperative Oncology Group performance status; CR: complete response; PR: partial response; SD: disease stable; PD: disease progression; WBC: white blood count; LDH: lactate dehydrogenase; Na: sodium; GLUT: γ-glutamyl transferase PLT: platelet count; BMI: body mass index; CEA: carcino-embryonic antigen; NSE: neuro-specific enolase; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio.